



Share



Tweet



Forward



## In this issue: Cantrixil™ and Anisina™

### Corporate events coming up

Dr Graham Kelly, Novogen CEO to present at the following

- Biotech & Money conference 3rd & 4th Feb, 2015, London
- Bio CEO & Investor conference 9th & 10th Feb, 2015, New York
- Sachs Cancer Bio Partnering & Investor conference 23rd Feb, 2015, New York

### US Investor Briefing Forum

**Dr Graham Kelly, Novogen Group** CEO and Executive Chairman, will present an overview of the clinical and corporate strategies for the Novogen Group for 2015-2016.

**Professor Gil Mor** PhD MD of Yale Medical School will present a talk entitled 'Cantrixil: A Novel Therapy to Target Cancer Stem Cells to Prevent Tumor Recurrence.'

**Dr Marc Symons** PhD of the Feinstein Institute for Medical Research at North Shore-LIJ will present a talk entitled "Development of TRXE-009 for the Treatment of Brain Cancer."



### US Investor Briefing Forum Details

We encourage you to book in advance

**When:** 2.00 pm 18 February 2015

**Where:** Yale Club (Saybrook Room), 50 Vanderbilt Ave, New York.

**Booking:** Please register your interest at [prue.kelly@novogen.com](mailto:prue.kelly@novogen.com)



### Ovarian Cancer Australia afternoon tea.

Novogen supports the advocacy of patients with ovarian cancer through its sponsorship of Ovarian Cancer Australia and the Ovarian Cancer National Alliance (USA).

As part of Ovarian Cancer Awareness month in Australia, Novogen will be hosting an afternoon tea (teal) with all donations to be made to the not-for-profit Ovarian Cancer Australia.

To be held at Hornsby Mall, Sydney, from 2.00 pm Friday 27th February.

For more information contact [prue.kelly@novogen.com](mailto:prue.kelly@novogen.com)



### Ovarian Cancer. Urgent call for action

Forty years ago following the introduction of chemotherapy, the **five-year survival rate** for women diagnosed with ovarian cancer was 36%. In 2014 it is 43%. The lack of any real progress in fighting this insidious disease confirms that current therapeutic approaches are not effective in preventing tumor recurrence. [Read more...](#)




### Cantrixil - could this be the long-awaited breakthrough treatment for ovarian cancer? We think so.

**Cantrixil has the potential to change the treatment landscape for ovarian cancer.** The active ingredient of Cantrixil, **TRXE-002**, is a highly effective killer of both cancer stem cells and regular (daughter) cancer cells in ovarian cancer. The secret behind the development of **TRXE-002** is the discovery of a molecular target that is common to both parent and daughter cancer cells. Disabling this target triggers the cancer cell's self-destruct button. [Read more...](#)



### Establishment of Medical Oncology Advisory Panel

Novogen has previously announced the appointment of Professor Paul De Souza as Chair of our Glioblastoma Medical Advisory Committee. Professor de Souza has agreed to take a more expansive role by providing advice on company-wide clinical oncology strategy and now will chair the Novogen Medical Oncology Advisory Panel. He has been joined by medical oncologists Professor Howard Gurney and Associate Professor Gavin Marx.




### Anisina - a means to make current chemotherapy more effective and safer

Australian university medical researcher, Professor Peter Gunning, once dreamt of finding a better and safer way to treat childhood cancers ... to be able to use cytotoxic drugs that killed cancer cells that didn't leave the child with a lifetime legacy of a damaged body. The anti-tropomyosin (ATM) drug technology was the result of that dream, and **Anisina** is the culmination of the search to bring that technology into the clinic. [Read more .....](#)



### TRXE-009 - bridging the link between brain cancer and melanoma

The Company recently announced the discovery that **TRXE-009** displayed particularly high activity against melanoma cells, to add to its high potency against brain cancer cells. In so doing, a remarkable story unfolded. [Read more.....](#)



### Project Jacob Hope - an exciting new frontier to conquer

Project Jacob Hope is a broad-ranging R&D program that is exploring the use of the Novogen super-benzopyran drug technology platform to develop effective treatments for a wide range of degenerative diseases where no treatments currently exist. Here we look at just one of these diseases in our sights – Sanfilippo Syndrome. [Read more...](#)

Contact us:  
[info@novogen.com](mailto:info@novogen.com)

**Our mailing address is:**  
PO Box 2333  
Hornsby Westfield 1635  
NSW Australia

[unsubscribe from this list](#) [update subscription preferences](#)